Articles tagged with Cancer Treatments
Researchers at Dana-Farber Cancer Institute and Broad Institute of MIT and Harvard uncovered critical insights into the biology of embryonal tumor with multilayered rosettes (ETMR), a rare and aggressive brain tumor affecting young children. Targeting FGFR and NOTCH receptors may represent a critical vulnerability in ETMR.
The European Society for Medical Oncology (ESMO) has released the latest version of the ESMO-MCBS scale, which measures the clinical benefit of cancer treatments. The new version incorporates 13 critical amendments to improve evaluation and accuracy, with a focus on patient preferences and toxicity annotations.
A rare form of childhood brain cancer called Diffuse Midline Glioma (DMG) hijacks gene control machinery to fuel its growth. A specific gene-silencing complex, CBX4/PCGF4-cPRC1, is essential for tumour growth and could be a promising drug target.
Researchers at The University of Osaka found that localized oxygen deficiency in colon tumors can promote tumor growth by transforming normal fibroblasts into inflammatory fibroblasts. These altered cells release factors that help tumors grow, offering a potential new target for cancer therapy.
A new study at the University of Turku identified conditions under which Bexmarilimab activates the immune system against cancer. The drug was shown to trigger B cell-mediated immune responses in healthy tissue adjacent to tumors. This could lead to more accurate patient selection and improved treatment outcomes.
A research team from the University of Copenhagen has developed a biotechnological method to produce Taxol, a widely used cancer drug. The new method involves cloning taxol-producing genes and inserting them into yeast cells, making it more cost-effective and sustainable than traditional chemical synthesis.
A new clinical trial has shown that a lower dose of radiotherapy can lead to higher levels of complete disappearance of cancer and fewer short-term side effects. The treatment approach, led by Professor David Sebag-Montefiore, aims to reduce the burden on patients and healthcare systems.
A study by Mass General Brigham found that patients with glioblastoma who received gabapentin lived longer than those who didn't. The medication was shown to confer a four-month survival benefit, with patients on gabapentin surviving an average of 16 months compared to 12 months for those without the drug.
Researchers found that stereotactic body radiotherapy (SBRT) is as safe as conventional treatment, with similar side effects and quality of life. SBRT shortens treatment time and may have biological advantages in targeting prostate cancer.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers have identified conditions under which ultra-high dose rate carbon ion beams can spare normal cells while maintaining tumor control, opening new possibilities for safer radiotherapy. The study reveals a cell-sparing effect under normoxic conditions using higher linear energy transfer values.
DiffInvex identifies evolutionary shifts in driver gene repertoires during tumorigenesis and chemotherapy, pinpointing mutational escape routes that let cancers resist treatment. The framework reveals which genes may ignite resistance to anticancer drugs, suggesting a core circuitry boosting strategy.
A new study uses explainable machine learning to predict metastasis and mortality in children with medulloblastoma, identifying key immune factors driving risk. The model provides a transparent approach to prognostic accuracy and supports personalized clinical decision-making.
Researchers found that current drinkers who consumed 14 or more drinks per week had a 25% higher risk of colorectal cancer compared to those who drank less than one drink per week. The study also presented data on a novel immunotherapy treatment for acute myeloid leukemia, showing greater success and fewer side effects.
The University of Texas at Arlington's nursing and physics team has developed a system to study alpha radiation, improving the effectiveness of radiation therapy. The team's research was recognized with the Best in Physics award at the American Association of Physicists in Medicine's annual meeting.
Researchers identified platelets, C-reactive protein, and chromogranin A as markers that can predict the failure of hormone-sensitive prostate cancer treatment. The study also found that miR-375 expression and lymphocyte-to-monocyte ratio are negative predictors for therapy failure in castration-resistant prostate cancer patients.
Researchers discovered 500 cryptic peptides found only in pancreatic tumors, which could be targeted by vaccines or engineered T cells to attack the cancer. The peptides were identified using immunopeptidomics and shown to slow down tumor growth in mice.
Researchers at MD Anderson Cancer Center have made breakthroughs in understanding pancreatic cancer metastases and identifying potential biomarkers for treatment-resistant pancreatic cancer. A comprehensive spatial map provides insights into lineage shifts in cancer cells transitioning from primary tumors to organ-specific metastases.
The ESMO Breast Cancer 2025 congress will cover topics such as circulating tumour DNA, immunotherapies, and emerging therapies for managing breast cancer. The event will feature key findings on predictive biomarkers, ctDNA, and tumour-infiltrating lymphocytes.
A new study reveals that exosomal lnc-TAF12–2:1 promotes bladder cancer progression through the miR-7847–3p/ASB12 regulatory axis. Silencing of lnc-TAF12–2:1 inhibited tumor growth and induced apoptosis, while its overexpression enhanced cell proliferation and migration.
A 10-year study confirms a one-week course of post-surgery radiotherapy is just as safe and effective as the traditional three-week regimen for early-stage breast cancer patients. This shorter schedule provides similar cancer control without additional long-term side effects.
A study published in The Lancet Regional Health – Europe found that patients with low household income were more likely to be diagnosed late and receive less effective treatment for liver cancer. This highlights the need for targeted screening in deprived areas to improve early diagnosis and survival rates.
Researchers have successfully tested a CRISPR/Cas9 gene-editing technique to enhance the immune system's fight against advanced gastrointestinal (GI) cancers. The treatment showed encouraging signs of safety and potential effectiveness in patients with stage IV colorectal cancer, halting tumor growth and even achieving complete responses.
A phase III clinical trial has shown that a two-and-a-half week course of precision radiotherapy is equally successful in beating prostate cancer as the standard eight-week approach. After 10 years, both options produced similar disease control rates and survival rates.
Researchers from the University of Southampton engineered a new type of super-strong antibody that triggers a stronger response from the immune system compared to naturally produced antibodies. The study confirms that making subtle increases in rigidity stimulates immune activity, creating a powerful immune response against disease.
Researchers investigated the clinical outcomes of concurrent TTFields therapy with CRT in patients with newly diagnosed glioblastoma, finding no significant difference in survival outcomes compared to adjuvant therapy. The study also showed comparable safety profiles for both treatment groups.
A Phase I clinical trial reveals that HSP-CAR30 CAR-T cell therapy promotes the expansion of memory T cells, leading to long-lasting responses and improved clinical outcomes in treated patients. The treatment exhibits a favorable safety profile, with no dose-limiting toxicities detected.
Researchers at TUM developed an AI-powered algorithm to predict kidney damage in prostate cancer patients undergoing lutetium-177 PSMA therapy. Early detection could enable personalized treatment adjustments to prevent organ damage.
A new CAR-T therapy, HSP-CAR30, has achieved positive results in a high proportion of patients with refractory CD30+ lymphoma. The treatment promotes the expansion of memory T cells, leading to durable responses and improved clinical outcomes.
AIC100 demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer, including anaplastic thyroid cancer (ATC) and relapsed/refractory poorly differentiated thyroid cancer (PTDC). The therapy showed significant tumor shrinkage and disease control in 56% of patients.
A new study highlights the success of a financial toxicity tumor board in reducing cancer treatment costs. The board has assisted over 9,321 patients with copay assistance and provided free medication to 16,495 patients, resulting in total savings of $393 million.
The ROME trial found that patients with concordant biopsy findings experienced improved survival outcomes when receiving tailored therapy based on genomic alterations detected in both tissue and liquid biopsies. This approach led to better overall survival, progression-free survival, and objective response rates compared to standard-of...
A study by Emory University researchers has found that spiritual health practitioners' personal experiences with psychedelics drive their careers in the emerging field of psychedelic-assisted therapy. The study introduced a novel training approach, emphasizing self-literacy and reflective learning to balance personal experience with cl...
Researchers create silk iron microparticles that can be guided using a magnet to deliver drugs and treatments precisely to sites in the body. The development has potential applications in regenerative medicine, cancer therapies, and cardiovascular disease treatment.
Regular exercise can reduce side effects of cancer treatment, such as heart damage, nerve damage, and brain fog. It also improves psychological wellbeing, sleep quality, and overall quality of life in people with cancer.
A randomized controlled trial demonstrates the feasibility and acceptability of integrating exercise and rehabilitation services into routine breast cancer care. The Comprehensive Oncology Rehabilitation and Exercise (CORE) program improved functional deficits, fitness, and strength in patients with stage I-III breast cancer.
Researchers develop nanoparticle-based therapy combining hydroxyl-enriched fullerenol and mTOR inhibitors to disrupt cancer cells' organelle communication system. The approach triggers a synergistic "nanomaterial + metabolic modulation" anticancer strategy, establishing a new hope for treating aggressive cancers.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
Researchers identified four specific genes linked to lethal stomach cancers, enabling potential targeted treatments and less aggressive procedures for some patients. The study's findings support a more personalized approach to treatment based on each patient's tumor biology.
Researchers developed a new method to determine optimal threshold time for restricted mean survival time analysis, improving statistical power in clinical and epidemiological studies. The method outperformed traditional statistical analysis methods in real-world scenarios, revealing clear differences between treatment groups.
A new imaging technique developed by IU scientists allows for the visualization of 25 cellular markers in intact bone marrow tissue without disruption. This advancement could support future drug development and therapies for conditions involving bone marrow.
Researchers have discovered genetic properties in prostate cancer that can be targeted to improve patient outcomes, particularly for Chinese men. The findings highlight the potential of precision medicine and more effective treatments.
This study examines primary reasons for traditional Chinese medicine adoption among Chinese cancer patients and their communication with oncologists. Key findings highlight the importance of culturally sensitive care, patient education programs, and addressing misconceptions about TCM.
A team of Singaporean scientists has released a comprehensive long-read RNA sequencing dataset, SG-NEx, to accelerate biomarker discovery and precision medicine. The dataset offers deeper biological insights into RNA complexity, enabling researchers to detect clinically relevant biomarkers and develop better treatments.
University of Oklahoma researchers create bioactive sugars to develop novel antibiotics against multi-drug-resistant infections in cancer patients. By using abundant, inexpensive, iron or metal-free, non-toxic blue light, the team can more easily and rapidly synthesize these important carbohydrates.
Researchers at Nagoya University found that patients with high-risk stigmata and invasive nodules in their pancreatic cysts had a significant impact on their survival. The presence of invasive nodules led to improved survival rates after surgery, while those without invasive nodules had favorable outcomes even without surgery.
Researchers have discovered RNA pseudouridine as a novel diagnostic target for colorectal cancer. The study found correlations between pseudouridine modifications and clinical markers, enabling potential non-invasive diagnosis. The findings provide a molecular framework for RNA epigenetics-based stratification and targeted interventions.
A UC Riverside-led study found that adult stem cells rely on histone chaperones to maintain their regenerative capacity. The researchers discovered that disrupting these proteins can lead to specific changes in stem cell identity, potentially guiding them into desired cell types.
Researchers developed fluorescent polyionic nanoclays that can be customized for medical imaging, sensor technology, and environmental protection. These tiny clay-based materials exhibit high brightness and versatility, enabling precise tuning of optical properties.
The University of Missouri is partnering with a consortium to design and license a new research reactor, NextGen MURR, which will produce critical medical isotopes for cancer treatment. The project aims to enhance Missouri's role as a leader in nuclear science and medical research.
Researchers analyzed CRC tumors with high tumor mutation burden to characterize BRAF-associated mutations and decipher their role in carcinogenesis. They found TMB-high tumors likely arise from a heterogeneous population of cells harboring numerous gene mutations distinct from driver oncogenes.
A new study found that a gene-based blood test can accurately predict skin cancer recurrence in stage III melanoma patients. The test measures circulating tumor DNA levels to identify those most likely to respond well to therapy.
A new study published in The Annals of Thoracic Surgery found that Medicaid expansion significantly improved access to timely treatment for patients with early-stage non-small cell lung cancer. High-volume hospitals associated with decreased postoperative complications and in-hospital mortality rates compared to low-volume hospitals.
A novel compound ML233 inhibits melanin production with no significant toxic side effects, offering a potential new strategy for treating pigment-related skin conditions. The study demonstrates promising results in reducing melanin synthesis and proliferation of melanoma cells.
The SNMMI Mars Shot Research Fund has awarded a $100,000 fellowship to Dr. Randy Ye for his research on FAPI PET imaging for detecting invasive lobular carcinoma. The study aims to assess the ability of FAPI PET and FDG PET to detect tumors and evaluate its impact on patient care.
Researchers discovered blocking CCR1 increases glucocorticoid sensitivity in multiple myeloma cells, offering a new strategy to improve treatment outcomes. The study found that high levels of CCR1 are linked to worse outcomes and plays a critical role in drug resistance.
Hepatocellular carcinoma is the most prevalent form of liver cancer, and liver transplantation offers a curative treatment option for appropriately selected patients. Bridging therapies, such as radiofrequency ablation and transarterial chemoembolization, can improve survival outcomes post-transplant by preventing tumor progression.
A multicenter retrospective study found that routine caudate lobe resection does not significantly improve long-term survival and recurrence for patients with HCCA. However, achieving a negative margin is crucial for improving prognosis.